Please login to the form below

Not currently logged in

Janssen's blood cancer drug Imbruvica approved in Europe


European commission licenses the first-in-class drug for two rare diseases

Regeneron top science employer, says survey

Ranked highest for third year in a row

FDA votes to keep severe warning on Pfizer’s Chantix

FDA headquarters White OakWill not relax anti-smoking drug's side effect warning

Amgen files lawsuit to block PCSK9 rivals

Amgen flagFirm suing Sanofi and Regeneron for patent infringement

AbbVie teams up with charities to raise awareness of bronchiolitis

more than a coldMost common cause of infant hospital admissions in winter

Baxter to launch HyQvia in US next week

Baxter buildingThe PID drug has been used in Europe for over a year

Biogen Idec launches online multiple sclerosis programme

Biogen Idec MS BlueprintMS Blueprint aims to help people with MS develop a personalised support plan

Boehringer's Ofev approved by FDA for rare lung disease

FDA headquarters White OakUS regulator also gives the green light to Intermune's Esbriet

Sanofi to work with Immune Design on herpes vaccine

Sanofi receptionBoth companies have separate vaccines in development but will pool resources

Fast and Slow ThinkingChanging behaviour with fast and slow thinking

Challenging the decision-making that underpins behaviour change

Latest appointments

Featured jobs

Subscribe to our email news alerts


Add my company
Red Door Communications

Red Door Communications (RDC) is the health and wellbeing communications consultancy that lives and breathes originality and is built on...

Latest intelligence

Online Physician Communities
M3 and partners win Digital Sales Aid Award
Wins for campaign to overcome limited doctor engagement with pharma-owned websites...
UK Customer Experience Awards 2014 Highlights
Stephanie Hall, Managing Director at Uptake Strategies, attended this year’s cross-industry UK Customer Experience Awards as a member of the judging panel for Business Transformation....
The heart of the matter - Part Three
Is pharma doing enough to maximise real world evidence?...